VIMIAN Vimian Group AB (publ)
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, education, and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and surgical and dental products to veterinary clinics and universities, including dentistry and companion animal orthopedics under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Vimian Group (STO: VIMIAN)
›
Vimian Group (STO: VIMIAN) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 1,025 employees.
The shares were at 44.00 SEK on 19 November 2026, up 43.0% over 52 weeks. Its 52-week range is 24.18 SEK to 44.20 SEK, and it trades at the top of that range.
At a market capitalisation of 23.24B SEK, it trades at 57.9 times trailing earnings and 33.1 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a premium of 62% for VIMIAN.
Vimian Group reports return on equity of 4.5%, an operating margin of 18.0% and revenue up 15.3% year over year.
Its debt exceeds its cash by 224.60M EUR, a debt-to-equity ratio of 0.34. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 42.30 SEK is 3.9% below the current price. The next earnings report is expected on 11 February 2027.